[Neurology]
| Autor: | J N, Chabwine, A R, Rossetti, L, Hirt, T, Kuntzer, M, Schluep, P, Michel, J F, Démonet, R A, du Pasquier, F G, Vingerhoets |
|---|---|
| Jazyk: | francouzština |
| Rok vydání: | 2012 |
| Předmět: |
Epilepsy
Multiple Sclerosis Fingolimod Hydrochloride Deep Brain Stimulation Valproic Acid Antibodies Monoclonal Parkinson Disease Genetic Therapy Phenylenediamines Stroke Polyneuropathies Treatment Outcome Muscular Diseases Neurology Ischemic Attack Transient Propylene Glycols Sphingosine Atrial Fibrillation Chronic Disease Dopamine Agonists Humans Anticonvulsants Carbamates Immunosuppressive Agents |
| Zdroj: | Revue medicale suisse. 8(323) |
| ISSN: | 1660-9379 |
| Popis: | In 2011, new oral anticoagulants for atrial fibrillation are available and the ABCD3-I score predicting stroke after TIA updates the ABCD2 score. New McDonald criteria allow faster MS diagnosis and the first oral treatment (fingolimod) for MS can be prescribed. A new anti-antiepileptic drug (retigabine) is available and sodium valproate has long term neurological adverse effects after in utero exposure. Among Parkinson disease treatments, deep brain stimulation is extending applications and dopamine agonists with extended release are as efficient and well tolerated as standard forms at long term scale. Monoclonal antibodies and immunosuppressant agents are proposed as good alternatives in the treatment of chronic dysimmune polyneuropathies. Gene therapy for the treatment of genetic myopathies is progressing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|